Brief: Relmada Therapeutics Reports Fourth Quarter Results
23/03/2023 20:06
March 23 (Reuters) - Relmada Therapeutics Inc RLMD.O :
* RELMADA THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS
FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS
* QTRLY NET LOSS FOR THREE MONTHS ENDED DEC 31, 2022, WAS
$37.9
MILLION, OR $1.28 PER DILUTED SHARE
* Q4 EARNINGS PER SHARE VIEW $-1.33 -- REFINITIV IBES DATA
Source text for Eikon: ID:nPn1QkVgRa
Further company coverage: RLMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million